cyrilzakka/clinical-trials huggingface dataset:
Efficacy of Maitland Mobilization in Shoulder Pathology

The shoulder is a mobile structure which generates a lot of pathologies. One of them is rotator cuff tendinosis. On the other hand, it has been investigated that Maitland is effective for reducing pain and for mobility in the cervical and lumbar spine and in joints such as the knee and ankle, however, there are few studies that confirm that it is effective in shoulder pathologies.So here the investigatprs want to study the effectiveness of Maitland as an adjunctive treatment for shoulder pathologies, comparing it with conventional physiotherapy treatment, in relation to the reduction of pain and increased mobility. For that the investigators have a randomized clinical trial with two group.

Group 1 receives tens, SW, conventional physiotherapy and exercises as treatment. Group 2 receives tens, SW, Mailtland, and exercises. An assessment is carried out at the beginning of the treatment, at the end and 2-4 weeks after finishing the treatment. The EVA ASES, DASH and SF-36 scales are included and the biomechanics study is used for the range of mobility.

Eligibility Criteria:
Inclusion Criteria:

* Have a shoulder pathology.
* Have a restriction at least of two ranges of movement of the shoulder.
* Sign the consent before starting the study.

Exclusion Criteria:

* Patients with a history of shoulder or neck surgery.
* Patients with neurological damage such as stroke or disease of Parkinson's, as well as those with rheumatism, osteoporosis, surgical fixation, or malignant tumors.
* Have a radiating pain in shoulder from a cervical injury.
* Pregnant patients.
* Patients who do not sign the consent before starting the study.
Multicenter RCT of the Clinical Effectiveness of Oncothermia With Chemotherapy in Metastatic Pancreatic Cancer Patients

Patients with pancreatic cancer often suffer from pain. Because of such a pain, their quality of life have seriously deteriorated. There have been a few studies that showed an effect for pain control by hyperthermia (heating the patient's body). However, there are several limitations in conventional hyperthermia.

In a previous pilot study (NCT02150135), we found the improvement of quality of life, function, and symptom.

From this background, the investigators tried to show the effect of "Oncothermia" with conventional chemotherapy for pain control, increasing quality of life, and anti-tumor treatment.


Eligibility Criteria:
Inclusion Criteria:

* Patients with pathologically confirmed pancreatic adenocarcinoma
* Patients with radiologically identified metastasis (CT or MRI)
* Patients with no history of previous chemotherapy
* Patients with ECOG score 0-2

Exclusion Criteria:

* Patients who have an experience of hyperthermia treatment
* Patients who have a difficulty of sensing heat
* Patients who have a skin graft or breast reconstruction surgery
* Patients who have a cardiac pacemaker or an implanted metal
* Pregnant or breast feeding women
* Patients with uncontrolled infection, diabetes, hypertension, ischemic heart disease, myocardial infarct within 6 months
* Patients who were treated with unproved drugs within 30 days
* Patients who have a serious disease which can affect the person's safety
* Patients who do not consent to the study
Effect of Progressive Relaxation Exercises and TENS on Women Delivering Via Cesarean

This study aimed to determine the effect of progressive relaxation exercises and transcutaneous electrical nerve stimulation administered to women delivering via cesarean section on acute pain, breastfeeding behavior, and comfort levels. Single-Blind, Randomized Controlled Study. This study was carried out in the obstetrics and gynecology clinic of a university hospital affiliated with the Ministry of Health in Turkey between August 20, 2018 and April 15, 2019. A total of 120 participants were randomly assigned to one of four groups, which included a transcutaneous electrical neural stimulation (TENS) group, a progressive relaxation exercises (PRE) group, a combined intervention (TENS+PRE) group, and a control group. Data were collected with a data collection form, the visual analogue scale (VAS), the LATCH breastfeeding diagnostic tool (LATCH), and the postpartum comfort scale (PCS). In the analysis of the data, numbers, percentages, and chi-square tests were used. Also, median values, Wilcoxon Signed-rank test, and Kruskal-Wallis H test were employed for continuous variables.


Eligibility Criteria:
Inclusion Criteria:

* women who were aged between 18 and 45,
* who were in the postoperative 8th hour,
* who had a transverse cesarean section,
* who, as well as their babies, did not develop any complications during pregnancy, delivery, and the postpartum period.

Exclusion Criteria:

* women who did not have an open wound on their body and/or allergic disease on their skin,
* who had cardiac arrhythmia or a pacemaker,
* who had a risk of epilepsy,
* who had epilepsy, eclampsia, kidney or liver disease,
* who had previously applied TENS and PRE methods,
* who were morbidly obese (with a BMI value of over 40),
* who used chronic opioids, antidepressants, and psychoactive drugs.
AcrySof IQ Toric A-Code Post-Market Clinical Study

The purpose of this study is to clinically confirm the rotational stability of a modified AcrySof IQ toric intraocular lens (IOL) in a Japanese population.

Patients will be examined pre-operatively to up to 3 years post-operatively. One eligible eye will be selected as a target eye for efficacy analysis. If both eyes are eligible, the eye in which the IOL is implanted first will be selected as the target eye.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of cataracts with planned cataract removal by phacoemulsification
* Calculated lens power within the available range
* Able to sign informed consent and complete all study visits
* Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

* Eye conditions as specified in the protocol
* Uncontrolled glaucoma
* Pregnancy, current or planned
* Other protocol-defined exclusion criteria may apply.
Evaluating PVI Using CMR

Using state of the art cardiac magnetic resonance imaging techniques, characterization of ablation lesions in the early phase after pulmonary vein isolation ablation in atrial fibrillation patients, and relate findings to the ablation scar at 3 months follow up and atrial fibrillation-free survival at 1 year.


Eligibility Criteria:
Inclusion Criteria:

* Adult patients (age ≥18 years old)
* Paroxysmal or persistent AF meeting guideline criteria.
* Anticipated PVI using index-guided radiofrequency ablation techniques.
* Availability of LGE-CMR images within 3 months before anticipated PVI.

Exclusion Criteria:

* History of catheter ablation
* History of cardiac surgery.
* History of chest radiation therapy
* Estimated glomerular filtration rate (eGFR) \<45 ml/min/kg
* Known (or suspected) allergic reaction to gadolinium
* Contraindications for CMR (such as claustrophobia, certain implants, devices, high body mass index).
* Inability to schedule CMR \<48h after PVI
* Long-term use of anti-inflammatory medication, except for the use of nonsteroidal anti-inflammatory drugs
* Autoimmune disease or chronic inflammatory illness.
* Pregnancy of breast feeding
Registry of Major Liver Resections Including ALPPS and Other Liver Resections in Two Stages

Recently a new method of induce similar hypertrophy in the liver as is observed after hepatectomy has been described and was given the eponym "ALLPS". "ALPPS" stands for Associating Liver Partition with Portal Vein Ligation for Staged Hepatectomy (ALPPS).

Since the procedure is used worldwide this international registry was created to enable tracking of cases performed worldwide for safety and outcomes and innovations by the groups involved as well as allows a non-randomized comparison to the conventional methods of portal vein occlusion.

The ALPPS registry is accessible online through the data portal www.allps.net. Registered members recieve access through a member ID and password. Data submission is supported by the SECUTRIAL software, supported by the Clinical Trials center of the University of Zurich.

All data submitted are anonymized before entry through the SECUTRIAL Software. Administration of the registry data is performed through the Department of Visceral and Transplantation Surgery in the University Hospital Zurich and the Clinical Trials Center of the University of Zurich, Switzerland, in collaboration with the Italian Hospital in Buenoas Aires, Argentina.

A Scientific Committee has been appointed to give approval for any data analysis. Any participating center may apply for data analysis.

Particiating International Centers have responsibility for the validity of the data submitted and the respective local institutional review procedures.

Eligibility Criteria:
Inclusion Criteria:

* All Patients who undergo the new ALPPS procedure
* Patients undergoing any other modification of ALPPS like portal vein embolization (PVE) or banding of the liver with portal vein ligation or embolisation or other liver resection in two stages resembling ALPPS_
* Male and Female patients 18 years to no limit
* Prior registering the data, patient was informed and did not object to the use of his/her anonymized medical data in this registry

Exclusion Criteria:

* No exclusion criteria apply for a registry
Monitoring Environmental Exposures and Behavioral Change

The goal of this study is to examine what effect real-time feedback on particulate matter (PM) air pollution levels has on risk recognition and behavior. The hypothesis is that real-time exposure feedback will change perceptions of risk and increase behaviors that avoid exposure to environmental risks. At least one representative household member in participating households will complete a questionnaire to fully understand environmental concerns, risk perceptions, and related behaviors. Half of the households will have PM monitors that continuously display real-time concentrations and an indication of the hazard level. The other participants will have the same device but it will only display the date and time. All participants will then be surveyed again: (a) immediately after sampling is complete (i.e., when the devices are removed from the home), (b) after 3 months and, (c) after 6 months. The goal of repeated surveys is to determine changing understanding of risks, how participating in research and/or receiving real-time exposure data may have changed participant behavior, and what concerns they continue to have. The questionnaire will include questions with categorical and/or quantitative answers (e.g., frequency of specific behaviors) so that changes in risk perception and behavior can be effectively analyzed.


Eligibility Criteria:
Participants must live in a household where at least one adult is a member of the N. Arapaho tribe who is a Primary Participant in the related exposure assessment study.
Use of High Flow Nasal Cannula During Sedation of Morbidly Obese Patients in the Endoscopy Suite

This study evaluates the ability of high flow nasal cannula versus nasal cannula to oxygenate morbidly obese patients undergoing moderate to deep sedation for gastrointestinal procedures.

The respiratory physiology of morbidly obese patients is altered due to restriction of the chest wall motion which decreases pulmonary compliance. In addition, anatomical changes lead to an increased incidence of airway obstruction in morbidly obese patients during periods of sedation. Both a typical nasal cannula and high flow nasal cannula provide supplemental oxygen to the patients to prevent desaturation and hypoxia. However, the higher flow rates of high flow nasal cannulas are able to produce allows for washout of carbon dioxide from the respiratory system aiding with ventilation and creates 3 to 5 cm H2O of positive end expiration pressure which helps prevent collapse of the airway aiding with oxygenation.

Eligibility Criteria:
Inclusion Criteria:

* Body Mass Index greater than or equal to 40
* Scheduled for a gastrointestinal endoscopy that requires MAC sedation

Exclusion Criteria:

* Body Mass Index less than 40
* Pregnant
* Require either invasive or non-invasive ventilation for respiratory failure
* Use home oxygen
* Ventilation is via a tracheostomy
* The procedure is emergent
Japanese BAY86-9766 Monotherapy Phase I Study

This is an uncontrolled, open-label, non-randomized phase I / pharmacokinetic study of oral BAY86-9766 to investigate the safety, tolerability, pharmacokinetics, and efficacy profiles in Japanese patients with advanced solid tumors


Eligibility Criteria:
Inclusion Criteria:

* Japanese patients, who are at least 18 years of age at the first screening examination/ visit, with advanced or refractory solid tumors not amenable to standard therapy.
* Histological or cytological documentation of non-hematologic, malignant solid tumor, excluding primary brain or spinal tumors, with no current involvement in the central nervous system (CNS)
* At least one measurable lesion or evaluable disease according to response evaluation criteria in solid tumors (RECIST) version 1.1
* Eastern cooperative oncology group performance status (ECOG-PS) of 0 or 1
* Life expectancy of at least 12 weeks

Exclusion Criteria:

* Use of any anti-cancer therapy including chemotherapy, investigational agents or devices and immunotherapy within 4 weeks of the first dose of study medication
* Uncontrolled hypertension defined as systolic blood pressure \> 150 mmHg or diastolic pressure \> 90 mmHg, despite optimal medical management
* Known human immunodeficiency virus (HIV) infection or chronic active hepatitis B or C
* Inadequate bone marrow, liver and renal function
* Inability to swallow oral medications or any condition that could affect the absorption of orally administered drugs
* Concomitant treatment with cytochrome P450 isoenzymes CYP3A4 inhibitors/inducers, and CYP2C19 inhibitors/ inducers
Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Elderly Subjects

There is evidence that aluminum phosphate (AlPO4) contained as an adjuvant in conjugate vaccines enhances the immune response in infants. There is no data so far evaluating whether this also applies to adults. The objective of this study is to compare the immune response of 2 different 13-valent pneumococcal conjugate (13vPnC) formulations with and without AlPO4 to select a formulation and to compare the immune response to the chosen 13vPnC formulation relative to the immune response to 23-valent pneumococcal polysaccharide vaccine (23vPS).


Eligibility Criteria:
Inclusion Criteria:

* Male and female adults 65 years of age and older.
* Determined by medical history, physical examination, and clinical judgment to be eligible for the study.
* Expected to be available for the duration of the trial (up to approximately 13 months).

Exclusion Criteria:

* Received previous immunization with 23vPS.
* Serious chronic disorders including metastatic malignancy
* Known or suspected hypersensitivity to any vaccine or vaccine components
HLH Patients - a Retrospective Study

Monocentric, observational, retrospective, no profit study aimed to analyze factors that are significantly impacting the outcome of patients diagnosed with HLH.

retrospective data collection to study: type of HLH familial vs secondary, sex, age, presence of infectious cause, involvement central nervous system ( SNC), hepatic involvement, presence of hemophagocytosis, presence of splenomegaly, presence of involvement of other organs, the value of neutrophils (PMN), the value of hemoglobin, platelets, albumin, triglycerides, ferritin, LDH, type of therapy and the response to therapy after 2 months

Eligibility Criteria:
Inclusion Criteria:

* Have received HLH diagnosis according to HLH 2004 criteria
* age ⥶18 years.
* followed at our facility between January 2004 and December 2021
* Whose parents have consented to participation and data processing

Exclusion Criteria:

* The study does not foresee specific exclusion criteria other than the non-compliance with the inclusion criteria
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy

The goal of this study is to determine whether a palliative care intervention (PEACE) can improve the quality of life and experiences of participants with Lymphoma, Leukemia, or Multiple Myeloma receiving adoptive cellular therapy (ACT). After completion of an open pilot, participants will be randomly assigned into one of two study intervention groups.

The names of the study intervention groups involved in this study are:

* Palliative care (PEACE) plus usual oncology care
* Usual care (standard oncology care)

Participation in this research study is expected to last for up to 2 years.

It is expected that about 90 people will take part in this research study.

This is a single-center, parallel-group, randomized controlled study to determine whether a palliative care intervention (PEACE) can improve the quality of life and experiences of participants with Lymphoma, Leukemia, or Multiple Myeloma receiving adoptive cellular therapy (ACT).

10 participants with planned ACT will be enrolled into an open pilot and will receive a palliative care intervention (PEACE) for the duration of treatment. Once the palliative care intervention has been refined by feedback from the pilot participants, the study will enroll 80 participants and will randomly assign the participants into one of two study intervention groups. Randomization means that a participant is put into a group by chance.

The names of the study intervention groups involved in this study are:

* Palliative care intervention (PEACE) plus usual oncology care
* Usual care (standard oncology care)

Participation in this research study is expected to last for up to 2 years.

It is expected that about 90 people will take part in this research study.

The American Society of Clinical Oncology is supporting this research study by providing funding support.

Eligibility Criteria:
Inclusion Criteria:

* Age 18 years or older.
* Ability to complete surveys in English or with assistance of an interpreter.
* Diagnosis of a hematologic malignancy.
* Receiving autologous adoptive cellular therapy (ACT) at MGH with an FDA approved cellular therapy product.

Exclusion Criteria:

* Impaired cognition or uncontrolled mental illness that prohibits study compliance based on the oncology clinician assessment.
* Already receiving palliative care (PC).
'Long COVID-19' in Suffolk and North Essex: Defining the Disease and Optimising Outcomes

To accurately describe the rehabilitation needs of individuals with post-COVID-19 syndrome up to 36 months after infection, allowing better diagnosis, triage and resource management. A major focus will be the impact on everyday life to return to normal activities.


Eligibility Criteria:
Inclusion criteria Individuals 18 years old and over (no upper age limit) Female and male Diagnosed with COVID-19 via PCR testing Or, Experienced symptoms of COVID-19 (new continuous cough, a high temperature, loss of taste and smell) And Clinically diagnosed with Post-COVID-19 Syndrome by their GP Participants who live within Suffolk and North East Essex

Exclusion criteria Individuals unable to consent for themselves Individuals without sufficient proficiency in English language to take part in telephone or video call, where the research team have been unable to make adjustments to enable their participation Individuals under 18 years old
Assessing the Efficacy of Repeat, Monthly Treatments of Alexandrite Laser for NF1-associated Cutaneous Neurofibromas (cNFs)

The goal of this clinical trial is to evaluate the tolerability and effectiveness of multiple treatments of Alexandrite (755 nm) Laser in those with Neurofibromatosis Type 1 (NF1) Cutaneous Neurofibromas (cNFs). The main questions it aims to answer are:

Will performing up to 6 months of treatment sessions with alexandrite laser will result in tolerable local skin reactions and reduction in both individual cNF size by \>50% as well as improved cNF appearance in the treated field? If there is a comparison group: Researchers will compare laser treatment with cooling to both laser treatment without cooling and an untreated control see if laser treatments are effective and if cooling makes treatment more tolerable.

Participants will:

* Receive up to 6 monthly laser treatments.
* Complete surveys asking about pain during and after treatments.
* Complete surveys asking about satisfaction with the treatments.
* Undergo 2D photography and 3D imaging of treatment areas.
* Optionally, receive biopsies of up to 6 treated lesions to investigate characteristics of tumors that respond well to treatment as well as non-respondent tumors.


Eligibility Criteria:
Inclusion Criteria:

* Participant is an adult ≥18 years of age.
* Participant has a diagnosis of NF1 based on germline genetic testing or by meeting ≥ 2 the following criteria:
* Family history of NF1
* Six or more light brown ("cafe-au-lait") spots on the skin
* Presence of two or more neurofibromas of any type, or one or more plexiform neurofibromas
* Freckling under the arms or in the groin area
* Two or more pigmented, benign bumps on the eye's iris (Lisch nodules)
* A distinctive bony lesion: dysplasia (abnormal growth) of the sphenoid bone behind the eye, or dysplasia of long bones, often in the lower leg
* Tumor on the optic nerve that may interfere with vision
* Participant is seeking treatment for cNF.
* Participants must have ≥ 12 paired cNF (6 to be treated without DCD, 6 to be treated with DCD) that are visible and measure at least 2 mm in size in the target treatment area. The target treatment area must be amenable to both laser treatments and surveillance with digital and 3D photography. Preferred locations are trunk (back or chest), arms and legs.
* Participant is able and willing to comply with all visit, treatment, and evaluation schedules and requirements.
* Participant is able to understand and provide written informed consent.
* Participant has no concurrent injury or wound in the target area.

Exclusion Criteria:

* Participant cannot give informed consent or adhere to study schedule.
* Participant is Fitzpatrick skin type V-VI.
* Participant is actively tanning during the course of the study.
* For female participants: participant is pregnant.
* Participant has any condition which, in the Investigator's opinion, would make it unsafe (for the participant or study personnel) to treat the participant as part of this research study.